Analysts predict that Bausch Health Companies Inc (NYSE:BHC) will report earnings of $1.15 per share for the current fiscal quarter, according to Zacks Investment Research. Six analysts have made estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $1.06 and the highest is $1.26. Bausch Health Companies posted earnings per share of $1.05 in the same quarter last year, which suggests a positive year-over-year growth rate of 9.5%. The business is expected to issue its next earnings results before the market opens on Wednesday, February 19th.
On average, analysts expect that Bausch Health Companies will report full-year earnings of $4.38 per share for the current year, with EPS estimates ranging from $4.30 to $4.50. For the next financial year, analysts forecast that the business will report earnings of $4.49 per share, with EPS estimates ranging from $3.79 to $4.86. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last posted its earnings results on Monday, November 4th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.13. Bausch Health Companies had a positive return on equity of 56.19% and a negative net margin of 7.25%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion.
Several equities analysts recently issued reports on BHC shares. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Bausch Health Companies in a research note on Monday, December 23rd. Piper Jaffray Companies increased their target price on Bausch Health Companies from $30.00 to $39.00 and gave the stock an “overweight” rating in a research note on Monday, December 30th. ValuEngine lowered Bausch Health Companies from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 17th. Zacks Investment Research lowered Bausch Health Companies from a “buy” rating to a “hold” rating and set a $33.00 target price on the stock. in a research note on Monday, December 16th. Finally, Goldman Sachs Group started coverage on Bausch Health Companies in a research note on Monday, December 2nd. They set a “neutral” rating and a $30.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $34.07.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Tokio Marine Asset Management Co. Ltd. increased its holdings in Bausch Health Companies by 3.5% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 17,800 shares of the company’s stock worth $389,000 after purchasing an additional 600 shares during the period. Pictet Asset Management Ltd. increased its holdings in Bausch Health Companies by 0.6% during the 2nd quarter. Pictet Asset Management Ltd. now owns 115,664 shares of the company’s stock worth $2,924,000 after purchasing an additional 700 shares during the period. D.A. Davidson & CO. increased its holdings in Bausch Health Companies by 2.5% during the 3rd quarter. D.A. Davidson & CO. now owns 30,360 shares of the company’s stock worth $663,000 after purchasing an additional 750 shares during the period. Cullinan Associates Inc. increased its holdings in Bausch Health Companies by 2.1% during the 3rd quarter. Cullinan Associates Inc. now owns 48,000 shares of the company’s stock worth $1,049,000 after purchasing an additional 967 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its holdings in Bausch Health Companies by 25.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,055 shares of the company’s stock worth $151,000 after purchasing an additional 1,025 shares during the period. Institutional investors own 57.52% of the company’s stock.
BHC traded down $0.22 during mid-day trading on Friday, hitting $29.51. 2,654,006 shares of the stock were exchanged, compared to its average volume of 3,418,329. The firm’s fifty day moving average is $29.48 and its two-hundred day moving average is $24.97. Bausch Health Companies has a 1-year low of $18.72 and a 1-year high of $31.97. The company has a current ratio of 1.15, a quick ratio of 0.86 and a debt-to-equity ratio of 9.17. The company has a market cap of $10.66 billion, a PE ratio of -16.77, a PEG ratio of 0.62 and a beta of 0.91.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Featured Article: What are some reasons analysts would give stocks a buy rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.